8-K: Ultragenyx Resubmits UX111 BLA for Sanfilippo Syndrome A

Ultragenyx Pharmaceutical Inc. has resubmitted its Biologics License Application for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A, to the FDA.

Summary

• Ultragenyx Pharmaceutical Inc. resubmitted its Biologics License Application (BLA) for UX111 (rebisufligene etisparvovec) AAV9 gene therapy to the U.S. Food and Drug Administration (FDA).
• The BLA seeks accelerated approval for UX111 as a treatment for Sanfilippo syndrome type A (MPS IIIA).
• The submission includes substantial longer-term data on neurologic benefit, supporting an intermediate clinical endpoint for accelerated approval, further supported by CSF heparan sulfate and other biomarker data, as agreed with the FDA.
• Comprehensive responses to chemistry, manufacturing, and controls (CMC)-related observations outlined in a Complete Response Letter (CRL) issued in July 2025 are included.
• Additional long-term clinical data from current patients, as requested by the Agency in the CRL, is also part of the resubmission.
• The FDA previously acknowledged that neurodevelopmental outcome data are robust and biomarker data provide additional supportive evidence.
• Updated clinical data, representing an additional year of follow-up, continue to show a durable treatment effect across multiple biomarkers and further clinical separation from natural history, while maintaining an acceptable safety profile.
• Detailed updates will be presented next week at the WORLDSymposium 2026 in San Diego.
• A Prescription Drug User Fee Act (PDUFA) action date is expected to be assigned within a month of resubmission.
• The Company anticipates up to a six-month review period from the date of resubmission, with a PDUFA date expected in the third quarter of 2026.
• If approved, UX111 will be the first approved therapy for Sanfilippo syndrome type A.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, as the company has successfully addressed prior regulatory concerns and strengthened its application with additional compelling clinical data for a first-in-class therapy.

Positives

• Resubmission of the Biologics License Application (BLA) for UX111 successfully addresses the Complete Response Letter (CRL) issued in July 2025.
• The submission includes substantial longer-term data demonstrating neurologic benefit and a durable treatment effect across multiple biomarkers.
• Updated clinical data show further clinical separation from natural history, indicating strong efficacy.
• The safety profile of UX111 remains acceptable.
• The FDA previously acknowledged the robustness of neurodevelopmental outcome data and supportive biomarker data.
• UX111 has the potential to be the first approved therapy for Sanfilippo syndrome type A, addressing a significant unmet medical need.
• The FDA granted UX111 BLA Priority Review in February 2025.

Negatives

• The initial BLA received a Complete Response Letter (CRL) in July 2025, indicating deficiencies that required resolution before approval.

Risks

• Uncertainty of clinical drug development and the unpredictable, lengthy process for obtaining regulatory approvals.
• Ability to successfully develop UX111.
• Ability to achieve projected development goals in expected timeframes.
• Risks related to adverse side effects.
• Risks related to reliance on third-party partners to conduct certain activities on the Company's behalf.
• Smaller than anticipated market opportunities for products and product candidates.
• Manufacturing risks, including limited experience in operating its own manufacturing facility.
• Ability of the Company and its third-party manufacturers to comply with regulatory requirements.
• Competition from other therapies or products.
• Matters that could affect the sufficiency of existing cash, cash equivalents, and short-term investments to fund operations.
• Impact on future operating results and financial performance.
• Timing of clinical trial activities and reporting results.
• Availability or commercial potential of Ultragenyx's products and drug candidates.

Future Outlook

The Company anticipates a six-month review period for the resubmitted BLA, with a PDUFA action date expected in the third quarter of 2026. If approved, UX111 would be the first approved therapy for Sanfilippo syndrome type A.

Industry Context

StockSavvy.ai notes that the resubmission of a BLA for a rare genetic disorder like Sanfilippo syndrome type A, especially after addressing a Complete Response Letter, is a significant event in the biotechnology sector. Success in developing therapies for orphan diseases often leads to substantial market opportunities due to unmet medical needs and potential for premium pricing, setting Ultragenyx apart in this niche.

Stakeholder Impact

• Shareholders: Potential for significant value creation if UX111 is approved, as it could be the first therapy for Sanfilippo syndrome type A.
• Patients with Sanfilippo syndrome type A: Hope for the first approved treatment for a devastating rare genetic disorder.
• Medical Community: Introduction of a novel gene therapy for a rare disease, potentially setting new standards of care.

Next Steps

• Detailed updates on UX111 will be presented next week at the WORLDSymposium 2026 in San Diego.
• A PDUFA action date is expected to be assigned within a month of resubmission.
• Anticipated six-month review period by the FDA.
• Expected PDUFA date in the third quarter of 2026.

Key Dates

Recommendation

The resubmission of the BLA for UX111, fortified with robust longer-term clinical data and comprehensive responses to the prior CRL, significantly de-risks the regulatory pathway for a potential first-in-class therapy for Sanfilippo syndrome type A. The FDA's prior acknowledgment of strong data and the priority review status further enhance the probability of approval, which would unlock a substantial market opportunity in a high-unmet-need rare disease. This positive regulatory momentum, coupled with the potential for a PDUFA date in Q3 2026, makes Ultragenyx an attractive investment.

Keywords

Ultragenyx, UX111, rebisufligene etisparvovec, AAV9 gene therapy, Sanfilippo syndrome type A, MPS IIIA, FDA, BLA, Biologics License Application, accelerated approval, gene therapy, rare disease, orphan drug, clinical data, biomarker, neurodevelopmental, PDUFA, WORLDSymposium, pharmaceutical, biotechnology